11 New Mexicos coverage was new as of the 2022 plan year, and the updated plan includes coverage of weight-loss medications as part of medically necessary treatment of morbid obesity and obesity. 12 Starting in 2025, North Dakota's EHB benchmark began to include coverage for weight-loss drugs, including GLP-1s for the treatment of morbid obesity
The FDA strongly recommended that the firm engage a third-party consultant with relevant sterile drug manufacturing expertise to conduct a comprehensive assessment of operations
Yu H, Ueckert S, Zhou L, et al
The market is expected to grow at a CAGR of 6.7%
The biologic significance of the different levels of serum DH activity was studied in two ways
Mounjaro activates two hormone receptors (GLP-1 and GIP), while Ozempic activates only one (GLP-1)